China-focused venture capital firm Qiming Venture Partners has led a RMB175 million (US$25 million) series A round in QIAGEN (Suzhou) Translational Medicine Co., a Chinese precision medicine solutions provider.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?